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The application of imaging biomarkers has provided new insights into the 
mechanisms of damage in multiple sclerosis (MS) and the risk of MS development 
and progression. The goal of eliminating all disease activity requires a timely 
escalation of treatment. This increasing complexity is compounded by the need to 
treat comorbidities.  
 
Multiple sclerosis (MS) is an increasingly complex disease in terms of its 
pathogenesis, comorbidities, prognosis and treatment, and successful patient 
management requires knowledge of this complexity. In 2015, there have been 
advances in our understanding of the mechanisms of the disease, ways in which to 
formulate patient prognoses, how best to escalate treatment escalation, and the 
role of comorbidities. All of these aspects need to be incorporated into an effective 
management plan (Fig. 1). 
 
The mechanisms that underlie the pathogenesis of MS are yet to be fully elucidated, 
but they are known to include a cascade of events that induce physical and cognitive 
deficits. A reduction in neuronal integrity and function that affects the grey matter 
compartment is thought to be the key pathological process that leads to cognitive 
impairment in MS. However, findings of a study published by Freeman et al.1 in 2015 
suggest that synaptic and/or dendritic damage occurs prior to quantifiable grey 
matter volume loss, and might reflect neuronal and axonal loss that contributes to 
clinical deficits. 
 
In this study, Freeman et al.1 used [11C]flumazenil ([11C]FMZ) PET, which quantifies 
GABAA receptor density in vivo, to identify grey matter damage beyond cortical 
lesions2. FMZ is an antagonist of the central benzodiazepine receptor, a component 
of the GABAA receptor complex that is present on axosomatic and axodendritic 
synapses throughout the cortical and subcortical grey matter. The number of 
[11C]FMZ binding sites per grey matter region was lower in several cortical areas (the 
parietal, cingulate, and insular cortices and the left frontal cortex) and subcortical 
regions (the thalamus, hippocampus and amygdala) in patients with MS than in 
healthy controls. Greater amounts of neuronal damage were seen in patients with 
secondary-progressive MS than in patients with relapsing–remitting MS (RRMS), but 
the most striking result was that [11C]FMZ binding was lower in patients with RRMS 
than in healthy controls, even in the absence of significant grey matter atrophy. A 
significant relationship was found between the level of cortical [11C]FMZ binding and 
performance on several cognitive tests. A goal of future research is to provide 
neuroprotective and reparative therapies that could be applied at such early stages 
of MS to stop or at least slow down neurodegeneration and reduce cognitive 
impairment in progressive MS3. 
 
Clinically isolated syndromes (CIS) represent a patient’s first neurological episode 
that is suggestive of MS. Most patients with CIS develop RRMS within 5 years of 
onset, and most patients with MS develop progressive MS 10–15 years after onset of 
MS. Although challenging, formulating a prognosis that accurately predicts the 
development of MS and the accumulation of neurological disability is crucial for 
designing successful treatment plans for individual patients. A key step towards such 
individualized treatment of patients with CIS is to “stratify” them into groups 
according to demographic, clinical, radiological and biological characteristics. 
Patients in different groups are likely to have a different risk of developing MS and 
long-term disability, so will benefit from different treatments at different time 
points. A study published by Tintore et al.4 in 2015 illustrates the importance of this 
step. 
 
Tintore and colleagues prospectively studied a single-centre cohort of 1,015 patients 
with CIS who were clinically and radiologically followed up for a mean of 6.8 years4. 
The results showed that ≥10 brain lesions visible with MRI at the onset of CIS was a 
“high-impact” prognostic factor that predicts the development of MS and disability. 
The presence of oligoclonal bands in the cerebrospinal fluid was a “medium-impact” 
prognostic factor that predicts the conversion from CIS to MS and the accumulation 
of disability. Presentation of CIS with optic neuritis and the use of a disease-
modifying treatment had a (probably marginal) protective effect against the 
development of MS and disability. Other demographic factors, such as gender and 
age at onset, were “low-impact” prognostic factors. The study had some 
methodological limitations, such as the number of patients who dropped out during 
follow-up (unavoidable in this type of longitudinal study) and the fact that the latest 
2010 McDonald diagnostic criteria were not used. Nevertheless, the results provide 
further clarity about the heterogeneous outcomes of patients with CIS and help to 
inform their prognosis.  
 
The ability to predict disease course is particularly important now that we have a 
range of new treatments for RRMS; although there is now a consensus that early 
treatment is optimum, the nature and timing of escalation to second-line treatment 
remains a challenge. The ultimate goal of such escalation is to increase the chance 
that patients reach a persistent, long-term status of ‘no evidence of disease activity 
(NEDA)’.5 
 
A central question that surrounds second-line treatment is whether natalizumab is 
more effective than fingolimod once failure of first-line treatment has been 
established. A head-to-head comparison between these two drugs is unlikely to be 
conducted, but Kalincik et al.6 in 2015 extracted data from the MSBase registry to 
compare the outcomes of treatment escalation to natalizumab or fingolimod in 
patients with MS who had experienced disease activity while receiving injectable 
disease modifying treatments. The relapse rate after switching to natalizumab was 
50% lower than after switching to fingolimod, with a corresponding increase in the 
proportion of relapse-free patients on natalizumab. Importantly, however, 6-month 
sustained disability progression rates did not differ between the two treatments. 
This finding highlights the need to identify new treatments that can slow or stop 
progression of MS, a major initiative being driven by the Progressive MS Alliance, 
who, in 2015, published an appraisal of current knowledge in this area and 
suggested future steps3. One other important consideration is that drug efficacy is 
only one factor that is considered by doctors and patients when discussing 
treatment escalation; treatment safety and tolerability, together with risk 
assessment7, are additional, important elements, particularly from the patient’s 
perspective.  
 
In addition to specific treatment approaches, a holistic approach to management, 
including a focus on well-being, is paramount, and identifying and managing 
comorbidities is an important element of this approach. The impact of comorbidities 
on clinical symptoms and disability progression in MS is becoming clear, and 
knowledge of how physical and mental comorbidities affect MS will improve 
management of the complexity of the disease. In 2015, Marrie et al.8 addressed the 
question of whether comorbidities are responsible for the reduced survival 
associated with MS. They used population-based administrative data to study 5,797 
people with MS and 28,807 healthy controls who were matched for sex, year of birth 
and geographical region. Median survival from birth was 75.9 years in the MS 
population, and 83.4 years in the control population, which corresponded to a 2-fold 
unadjusted increase in the hazard of death in the MS population. Comorbidities 
(depression, diabetes and ischaemic heart disease) were associated with increased 
mortality in MS, but did not confer a greater risk of mortality in the MS population 
than in the control population. Mortality from infectious diseases and diseases of the 
respiratory system was higher in the MS population than in the control population. 
These findings extend the results of previous studies that reported an effect of 
comorbidity on the diagnosis of and disability in MS9 , suggesting that treatment and 
prevention of comorbidities improves survival in MS. Future research will fill 
important gaps in our knowledge about the worldwide epidemiology of comorbidity 
in MS10.  
 
These recent advances in MS research and clinical trials will help clinicians to 
manage the complexity of MS in clinical practice and will inform future research in 
the field. We anticipate that 2016 will bring major advances in the treatment of 
progressive MS, which remains a substantial unmet need.3  
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Figure 1. Towards successful management of the complexity of multiple sclerosis.  
 
Key advances 
 Synaptic and/or dendritic loss might be an early pathological abnormality in 
multiple sclerosis (MS) and precede MRI-detectable volume loss1.  
 In clinically isolated syndrome, oligoclonal bands and the lesions detected with 
brain MRI are medium-impact and high-impact prognostic factors, respectively, 
for the development of MS and early disability4.   
 The relapse rate was 50% lower when patients switched from injectable disease-
modifying treatment to natalizumab than when they switched to fingolimod, but 
no difference was observed in disability progression6. 
 Although MS patients live longer than before, their life expectancy remains 
~7 years shorter than that of a matched healthy population; treatment of 
comorbidities might improve survival8. 
 The Progressive MS alliance is driving an initiative to identify new treatments to 
slow or stop progression of MS3.  
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